Effects of gadoxetic acid on liver elasticity measurement by using magnetic resonance elastography

Magnetic Resonance Imaging

Volumn 30, Issue 1, 2012, Pages 128-132

  Motosugi, Utaroh ^a   Ichikawa, Tomoaki ^a   Sou, Hironobu ^a   Sano, Katsuhiro ^a   Muhi, Ali ^a   Ehman, Richard L ^b   Araki, Tsutomu ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b MAYO CLINIC   (United States)

Author keywords

Gadoxetic acid (Gd EOB DTPA); Liver cirrhosis; MR elastography

Indexed keywords

GADOXETIC ACID;

ADULT; AGED; ARTICLE; COMPLIANCE (PHYSICAL); CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DRUG EFFECT; ELASTOGRAPHY; FEMALE; HUMAN; LIVER COMPLIANCE; LIVER SINUSOID; MAGNETIC RESONANCE ELASTOGRAPHY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RIGIDITY; STUDENT T TEST; THORAX WALL; VIBRATION;

AGED; AGED, 80 AND OVER; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; ELASTIC MODULUS; ELASTICITY IMAGING TECHNIQUES; END STAGE LIVER DISEASE; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 82955194495     PISSN: 0730725X     EISSN: 18735894     Source Type: Journal    
DOI: 10.1016/j.mri.2011.08.005     Document Type: Article

References (29)

1. Perrillo R.P. The role of liver biopsy in hepatitis C. Hepatology 1997, 26(3 Suppl 1):57S-61S.
2. Yoshida H., Shiratori Y., Moriyama M., Arakawa Y., Ide T., Sata M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999, 131(3):174-181.
3. Tsukuma H., Hiyama T., Tanaka S., Nakao M., Yabuuchi T., Kitamura T., et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993, 328(25):1797-1801.
4. Glaser K.J., Felmlee J.P., Manduca A., Ehman R.L. Shear stiffness estimation using intravoxel phase dispersion in magnetic resonance elastography. Magn Reson Med 2003, 50(6):1256-1265.
5. Rouviere O., Yin M., Dresner M.A., Rossman P.J., Burgart L.J., Fidler J.L., et al. MR elastography of the liver: preliminary results. Radiology 2006, 240(2):440-448.
6. Talwalkar J.A., Yin M., Fidler J.L., Sanderson S.O., Kamath P.S., Ehman R.L. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 2008, 47(1):332-342.
7. Ehman R.L. Science to practice: can MR elastography be used to detect early steatohepatitis in fatty liver disease?. Radiology 2009, 253(1):1-3.
8. Huwart L., Sempoux C., Salameh N., Jamart J., Annet L., Sinkus R., et al. Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Radiology 2007, 245(2):458-466.
9. Faria S.C., Ganesan K., Mwangi I., Shiehmorteza M., Viamonte B., Mazhar S., et al. MR imaging of liver fibrosis: current state of the art. Radiographics 2009, 29(6):1615-1635.
10. Venkatesh S.K., Yin M., Glockner J.F., Takahashi N., Araoz P.A., Talwalkar J.A., et al. MR elastography of liver tumors: preliminary results. AJR Am J Roentgenol 2008, 190(6):1534-1540.
11. Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007;5(10):1207-13 e1202.
12. Ba-Ssalamah A., Uffmann M., Saini S., Bastati N., Herold C., Schima W. Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions. Eur Radiol 2009, 19(2):342-357.
13. Ichikawa T., Saito K., Yoshioka N., Tanimoto A., Gokan T., Takehara Y., et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 2010, 45(3):133-141.
14. Hamm B., Staks T., Muhler A., Bollow M., Taupitz M., Frenzel T., et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995, 195(3):785-792.
15. Motosugi U., Ichikawa T., Tominaga L., Sou H., Sano K., Ichikawa S., et al. Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time?. Eur Radiol 2009, 19(11):2623-2629.
16. Reimer P., Rummeny E.J., Shamsi K., Balzer T., Daldrup H.E., Tombach B., et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 1996, 199(1):177-183.
17. Choi J.S., Kim M.J., Choi J.Y., Park M.S., Lim J.S., Kim K.W. Diffusion-weighted MR imaging of liver on 3.0-Tesla system: effect of intravenous administration of gadoxetic acid disodium. Eur Radiol 2010, 20(5):1052-1060.
18. Saito K., Araki Y., Park J., Metoki R., Katsuyama H., Nishio R., et al. Effect of Gd-EOB-DTPA on T2-weighted and diffusion-weighted images for the diagnosis of hepatocellular carcinoma. J Magn Reson Imaging 2010, 32(1):229-234.
19. Tamada T., Ito K., Yoshida K., Sone T., Murakami K., Kanki A., et al. T2-weighted magnetic resonance imaging of the liver: evaluation of the effect in signal intensity after Gd-EOB-DTPA enhancement. J Comput Assist Tomogr 2010, 34(2):182-186.
20. Tanimoto A., Lee J.M., Murakami T., Huppertz A., Kudo M., Grazioli L. Consensus report of the 2nd international forum for liver MRI. Eur Radiol 2009, 19(Suppl 5):S975-S989.
21. Brown M.A., Semelka R.C. MRI Basic Princples and Applications 2003, Wiley-Liss, Hoboken (NJ). 3rd ed.
22. Manduca A., Oliphant T.E., Dresner M.A., Mahowald J.L., Kruse S.A., Amromin E., et al. Magnetic resonance elastography: non-invasive mapping of tissue elasticity. Med Image Anal 2001, 5(4):237-254.
23. Talwalkar J.A., Yin M., Venkatesh S., Rossman P.J., Grimm R.C., Manduca A., et al. Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension. AJR Am J Roentgenol 2009, 193(1):122-127.
24. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994, 20(1 Pt 1):15-20.
25. Castera L., Vergniol J., Foucher J., Le Bail B., Chanteloup E., Haaser M., et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128(2):343-350.
26. Luciani A., Vignaud A., Cavet M., Nhieu J.T., Mallat A., Ruel L., et al. Liver cirrhosis: intravoxel incoherent motion MR imaging-pilot study. Radiology 2008, 249(3):891-899.
27. Patel J., Sigmund E.E., Rusinek H., Oei M., Babb J.S., Taouli B. Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging 2010, 31(3):589-600.
28. Motosugi U., Ichikawa T., Sou H., Sano K., Muhi A., Koshiishi T., et al. Magnetic resonance elastography of the liver: preliminary results and estimation of interrater reliability. Jpn J Radiol 2010, 28:623-627.
29. Nakamura Y., Ohmoto T., Saito T., Kajima T., Nishimaru E., Ito K. Effects of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid on T2-weighted MRCP. Magn Reson Med Sci 2009, 8(4):143-148.